Gene study aims to personalize common heart drug

NCT ID NCT03051282

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how genetic differences affect the activation of enalapril, a common blood pressure medication. Researchers gave 21 healthy volunteers enalapril for a week and measured drug levels in their blood. The goal was to see if a specific gene variant (G143E) changes how the body processes the drug, which could lead to more personalized dosing in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

enalapril

What this could lead to

If successful, this could help doctors personalize ACE inhibitor dosing based on a person's genetics, improving effectiveness and reducing side effects.

What could go wrong

This is a small, early-stage study in healthy volunteers, not patients. Results may not translate to real-world treatment or account for other factors affecting drug response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States